3D tumor models for CAR-T-cell therapy optimization

03:253 years ago

Chimeric antigen receptor (CAR) T-cell therapy accounts for one of the most promising therapeutic advances in cancer immunotherapy. In this form of adoptive cell transfer, T-cells of a patient are engineered to express so-called ‘CARs’, in which the antigen-recognition capacity of antibodies is combined with T-cell activating domains. So far, CAR-T-cell therapy obtained its most impressive results in hematological malignancies resulting in the approval of five CAR-T cell products by the FDA for hematologic indications. However, CAR-T-cell therapy has not mirrored its success in solid tumors. The poor efficacy of CAR-T-cell therapy in solid tumors has, in part, been attributed to the lack of understanding in how CAR-T-cells function in a solid tumor microenvironment. Classical validation methods rely on the use of specificity and functionality assays in 2D models against adherent target cells or target cells in suspension. Yet, by using these models, observations made in vitro may differ greatly to an in vivo situation where tumors are engrafted in 3D structures. We developed a more relevant and translational 3D tumor model using eGFP+ target cells. This allows us to couple 3D tumor cell killing by CAR-T-cells to live-cell imaging, providing an efficient quantification of target cell death. As proof- of-concept, we used a 3D model of eGFP+ glioblastoma cells and CAR-T-cells targeting a pan-cancer antigen. This 3D glioblastoma model allowed us to show that classical scFv-based CAR-T-cell therapy of glioblastoma cells can be improved by nanoCAR-T-cells. Furthermore, combining nanoCAR-T-cell therapy with a genetic approach of nanobody-based anti-PD-L1 immune checkpoint blockade further increased the cytotoxicity of the nanoCAR-T-cell therapy.

Related

The NAM Navigator: A unique repository for information on the validation and acceptance of New Approach Methodologies
Projects and initiatives
HealthToxicology

The NAM Navigator: A unique repository for information on the validation and acceptance of New Approach Methodologies

The NAM navigator is an innovative knowledge portal to navigate you to and through valuable information on the development, standardization, validation and acceptance of New Approach Methodologies (NAM). The NAM Navigator acts as an online guide that provides specific information needed in each of these steps, thereby increasing the broad use of animal-free innovations. Follow the link in the video to start navigating!
02:136 days ago
VHP4Safety project
Projects and initiatives
HealthToxicologyIn vitroIn silico

VHP4Safety project

The safety testing of chemicals and pharmaceuticals traditionally relies on animal studies. However, these raise ethical concerns and often fail to accurately predict human responses. New scientific developments offer opportunities to build a Virtual Human Platform (VHP) for safety assessment, a platform that enables assessment based solely on human physiology and biology, integrating data from in vitro and in silico models. This video explains how we are developing the VHP through an interdisciplinary approach. Read the paper in the videolink or visit or VHP4Safety (https://vhp4safety.nl/) for more information.
03:1612 days ago
AI agents for safer science: How AI is Changing Chemical Risk Assessment
Innovation examples
HealthToxicologyIn silico

AI agents for safer science: How AI is Changing Chemical Risk Assessment

This video introduces a novel approach to chemical safety, where intelligent digital agents guided by large language models support scientists in making faster, more transparent decisions. By automating complex workflows and integrating tools like the OECD QSAR Toolbox, these agentic systems help prioritise research, reduce reliance on animal testing, and pave the way for safer, more sustainable innovation.
02:5620 days ago
User Research in developing the virtual human platform
Innovation examples
ToxicologyPolicy

User Research in developing the virtual human platform

Digital tools can support the phasing out of animal-based tests and data in chemical risk assessment. This is one of the core promises of the Virtual Human Platform. The potential contribution of digitalization is linked to the acceptance and adoption of tools, methods, and data by stakeholders in several societal sectors. To facilitate the integration of stakeholders in the configuration of digital tools, Dr. Isaac Ortega Alvarado and colleagues gather insights from risk assessors in their role as users. Risk assessors are the ones who actualize chemical risk assessment and its standards through their practices. With this perspective, this research contributes to understanding the development and implementation of digital tools as embedded in social processes of construction and reception.
01:1542 days ago